M etabolic demand is an important determinant of the degree of mechanical recovery of the myocardium after a period of transient ischemia.'-4 Under aerobic conditions, fatty acids are the preferred energy substrate of the myocardium. During ischemia, however, fatty acid oxidation decreases, and a greater proportion of ATP production is derived from glucose.5,6 Energy substrate preference by the reperfused myocardium has not been well defined, and studies addressing this issue have yielded conflicting results. Positron emission tomography studies in dogs suggest a shift from predominant fatty acid utilization to predominant glucose utilization in hearts reperfused after a period of ischemia.7 However, measurement of fatty acid oxidation in swine and canine hearts reperfused after a period of ischemia suggests that fatty acid utilization is increased rather than decreased.89 In addition, measurement of glucose and palmitate extraction in reperfused ischemic dog hearts also indicates that fatty acids remain the preferred energy substrate of the heart.10 This contrasts with ['4C]palmitate infusion studies in humans, which suggest that palmitate utilization decreases during reperfusion."1 A number of factors may explain these discrepancies.
First, serum levels of fatty acids are an important determinant of myocardial substrate use5 and can increase dramatically after myocardial ischemia.1213 Second, endogenous myocardial triglyceride and glyco-gen stores may provide endogenous fatty acids and glucose, respectively, for oxidative metabolism.514 Perfusion of the myocardium with radiolabeled substrates may also result in incorporation of these exogenous substrates into endogenous pools. Other factors such as myocardial workload, hormonal influences, and neuronal input to the heart may also alter oxidative metabolism both directly and indirectly. Ideally, all of these variables should be controlled in a study of metabolic substrate use in reperfused myocardium.
In this study, we used the isolated perfused rat heart to control these variables and to quantitate myocardial energy substrate use by the heart after a period of transient global ischemia. We determined that rates of fatty acid and glucose oxidation in reperfused myocardium are similar to those in the preischemic aerobic myocardium. Furthermore, stimulation of glucose oxidation during reperfusion improved mechanical recovery. Combined with our previous work,15-17 our results suggest that depression of glucose oxidation rates in the presence of fatty acids may contribute to mechanical "stunning" in reperfused ischemic hearts.
Materials and Methods Heart Perfusions
Male Wistar rats (200-250 g) were anesthetized with an injection of sodium pentobarbitol (60 mg/kg i.p. Figures 1 and 2 , steady-state oxidative rates were also achieved within 20 minutes of aerobic reperfusion of hearts subjected to a 25-minute period of transient ischemia.
Tissue Metabolite Deterninations
At the end of the perfusions, hearts were freezeclamped with Wollenberger clamps cooled to the temperature of liquid N2. Frozen ventricular tissue was weighed and powdered in a mortar and pestle cooled to the temperature of liquid N2. A portion of the powdered tissue was used to determine the dryto-wet ratio. By use of this ratio, as well as the total frozen ventricular weight and dried atrial weight, the total dry weight of the heart was determined.
Extraction of long chain acylcarnitine and ATP was as described previously.18 These metabolites were extracted, with the aid of a mortar and pestle, from approximately 400 mg frozen tissue into 1.5 ml ice-cold perchloric acid (6% wt/vol) containing 15 mM dithiothreitol. The perchloric acid precipitate (containing long chain acylcarnitine) was separated from the acid-soluble intermediates as described previously.18 Long We also determined that the CPT 1 inhibitor Etomoxir could overcome the detrimental effect of fatty acids after ischemia. Therefore, we determined the effect of Etomoxir on glucose oxidation in reperfused hearts. Table 2 (Table 2) .
Accumulation of Fatty Acids in Myocardial Triglycerides During Reperfusion
Measurement of fatty acid oxidation using exogenous substrate labeled with 14C must allow for possible incorporation of the radiolabel into myocardial triglycerides. Similarly, endogenous triglycerides can also supply unlabeled fatty acids for oxidative metabolism. Therefore, myocardial triglyceride content and [14C]palmitate content of triglycerides were determined in hearts frozen at the end of the perfusion period. As shown in Table 3 , total triglyceride content in fatty acid-perfused hearts was not significantly different between nonischemic hearts or ischemic hearts reperfused in the presence or absence of Etomoxir. Myocardial triglyceride levels in freshly excised nonperfused rat hearts range from 17 to 20 ,umol/g dry wt (equivalent to 54-60 ,umol free fatty acid as triglycerides per gram dry weight). In both nonischemic and reperfused ischemic hearts, perfu- We also measured long chain acylcarnitine levels in nonischemic and reperfused ischemic hearts (Table 3) . Compared with fatty acid-perfused nonischemic hearts, levels of long chain acylcarnitine were slightly elevated in reperfused ischemic hearts. We also demonstrate that in the presence of high concentrations of fatty acids, glucose oxidation in reperfused myocardium is markedly depressed (Figure 1) . This parallels what has previously been demonstrated in the nonischemic heart.5 Combined with our earlier work,19 the data suggest that this marked suppression of glucose oxidation may contribute to the "myocardial stunning" seen in hearts reperfused in the presence of palmitate. Furthermore, the beneficial effect of the CPT 1 inhibitor Etomoxir is correlated with its ability to stimulate glucose oxidation in the fatty acid-perfused heart (Tables 1 and 2 and Reference 15). Another observation that can be made from these experiments is that exogenous fatty acids are incorporated to an increased extent into endogenous myocardial triglycerides in reperfused ischemic hearts. Reperfused hearts incorporated 26 15, 17 In this study, palmitate markedly depressed glucose oxidation during reperfusion. In the presence of glucose and fatty acid concentrations that are similar to serum levels seen clinically, glucose oxidation provided only 6% of total myocardial ATP production from exogenous substrates. This is significantly lower than the 30-40% of total ATP production from glucose in nonischemic hearts perfused with lower concentration of fatty acids.56 Theoretically, the low glycolytic flux in reperfused hearts exposed to high concentrations of fatty acid could contribute to the depressed reperfusion recovery since decreases in anaerobic glycolytic ATP production decrease the ratio of ATP produced/02 consumed. In addition, it has been postulated that glycolytically produced ATP may be preferentially used by membrane ion pumps.33,34 Therefore, a decrease in glycolytic flux may result in a delayed reestablishment of transmembrane ion gradients during reperfusion, contributing to subsequent Ca2+ overload. We have yet to determine if the depressed recovery of fatty acid-perfused hearts is accompanied by an increase in intracellular Ca2+ accumulation. CPT 2-tetraglycic acid,37 and Etomoxir15 all have a beneficial effect in the experimental setting of ischemia. This effect has been suggested to occur as a result of a lowering of myocardial long chain acylcarnitine levels.35,36 However, we have demonstrated that Etomoxir can improve recovery of fatty acid-perfused ischemic hearts without lowering long chain acylcarnitine levels.15 At low doses (10-9 M), Etomoxir markedly lowers long chain acylcarnitine levels in fatty acid-perfused hearts but does not stimulate glucose oxidation or protect the reperfused ischemic heart. This decrease is not accompanied by a decrease in palmitate oxidation, suggesting that CPT 1 inhibition can occur without a concomitant decrease in fatty acid oxidation. At a higher dose (10`8 M), Etomoxir lowers long chain acylcarnitine, stimulates glucose oxidation, and protects the reperfused ischemic heart.17 Stimulation of glucose oxidation by Etomoxir was also seen in the absence of added palmitate. This probably was a result of Etomoxir overcoming inhibition of glucose oxidation by endogenously supplied fatty acids. Myocardial triglycerides can serve as a source of fatty acids in hearts deprived of exogenous fatty acids.5 As demonstrated here, a very large dose of Etomoxir (10-6 M) no longer lowers long chain acylcarnitine levels but does stimulate glucose oxidation and does protect the reperfused ischemic heart. These results suggest that the beneficial effect of Etomoxir is due to a stimulation of glucose oxidation. The increase in glucose oxidation may occur as a result of Etomoxir partially overcoming fatty acid inhibition of pyruvate dehydrogenase, although this has yet to be determined. Stimulation of glucose oxidation may also explain the beneficial effect of CPT 1 inhibitors in other studies. To our knowledge, however, no other studies have described the effects of CPT 1 inhibition on glucose oxidation in the reperfused ischemic heart.
In summary, we demonstrate that fatty acids are the primary energy substrate oxidized by working rat hearts reperfused after a period of transient ischemia. In addition, low rates of glucose oxidation may contribute to the depressed recovery of function seen in hearts reperfused in the presence of high concentrations of fatty acids. CPT 1 inhibition appears to have a beneficial effect in the reperfused myocardium by stimulating glucose oxidation. Although the clinical importance of agents that modify fatty acid flux in humans remains unresolved, our data suggest that control of markedly elevated plasma fatty acid levels or stimulation of glucose oxidation in the reperfused ischemic myocardium may be of clinical benefit after myocardial ischemia or infarction in humans.
